Aprea Therapeutics (APRE) Stock Soars As Wedbush Sets $3 Price Target
One of the worst scourges of our time, experts estimated that nearly two million new cancer cases were diagnosed last year. However, the advent of advanced therapeutics that the coronavirus pandemic engendered bodes well for biotechnology firms like Aprea Therapeutics (NASDAQ:APRE), which on Friday received positive coverage from Wedbush analyst Robert Driscoll. In response, APRE stock is up over 14%…